There is no standard or regulatory-approved dosage for the DSIP peptide. Published human studies have used experimental intravenous protocols under clinical supervision. These cannot be translated into a safe self-administration regimen. Most human DSIP studies were conducted in the 1980s and early 1990s. Researchers typically administered doses in nanomoles per kilogram of body weight rather than as a fixed number of milligrams. The best-documented sleep studies used a slow intravenous infusion of 25 nmol/kg. One repeated-administration study used 30 nmol/kg six times over the course of one week [1–6].
These protocols were developed to investigate specific scientific questions under controlled laboratory conditions. They did not determine the recommended dose, the maximum tolerated dose, the best route of administration, or the long-term dosing schedule.
This distinction is important because online DSIP protocols often describe subcutaneous or intranasal administration, fixed amounts expressed in micrograms, bedtime use, cycles, and vials labeled as 2 mg, 5 mg, 10 mg, or 15 mg. Such practices do not correspond to the methods used in published human studies.
The vial size merely determines the declared amount of material contained in the package. It is not a dose, duration of therapy, or proof of pharmaceutical quality. Therefore, the dosage table below should be treated as a summary of methods used in research, and not as an individual dosing guide.
Is there a standard dosage for DSIP?
No standard dose of DSIP has been established for sleep, insomnia, withdrawal symptoms, pain, post-exercise recovery, longevity, or any other proposed use.
Before a standard dose is determined for a drug, dose-escalation studies, pharmacokinetic and pharmacodynamic data, adequately powered randomized trials, systematic safety monitoring, and evaluation of the specific formulation by regulatory authorities are usually required.
DSIP has not undergone such a development program. Historical studies evaluated only a small number of doses in small participant groups, typically using intravenous administration. Modern studies have not determined the minimum effective dose, the dose-response relationship in insomnia, the maximum tolerated dose, or how to adjust dosage for age, renal or hepatic function, concomitant medications, pregnancy, or sleep-disordered breathing.
The term „DSIP dosage” can also refer to several different substances. Native DSIP, also known as emideltide, is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Phosphorylated DSIP, truncated analogs, KND-bound peptides, DSIP-containing preparations such as Deltaran, and modified fusion peptides designed to cross the blood-brain barrier are distinct research subjects. Doses tested for one form cannot automatically be applied to another.
The presence of the substance in the regulatory database also does not resolve the issue of dosage. The substance registry of the US Food and Drug Administration (FDA) lists emideltide as a specific chemical substance, but clearly states that the assignment of a Unique Ingredient Identifier does not imply a regulatory assessment or approval of the substance [7].
DSIP is not an FDA- or EMA-approved drug for the treatment of insomnia. Therefore, there is no approved product characteristic specifying an official dose or administration schedule.
DSIP doses used in published studies
The most transparent human dosing data comes from small sleep and insomnia studies in which 25 or 30 nmol/kg of DSIP was administered intravenously.
In the first controlled human sleep study, six healthy volunteers received a slow intravenous infusion of 25 nmol/kg in the morning as part of a double-blind, crossover study. Directly increased sleep pressure was observed in the participants, and subsequent nighttime measurements suggested faster sleep onset and higher sleep efficiency. However, the researchers did not observe the typical sedative effect that would be expected from a classic hypnotic drug [1].
In another study, six middle-aged individuals with chronic insomnia were administered 25 nmol/kg intravenously. The sleep-inducing effects were mainly evident during the second hour, following a slight increase in arousal observed during the first hour [2]. These very small studies helped formulate further scientific hypotheses but did not establish a universal dose.
A 1984 review of studies on insomnia described improvements following single doses of 25 nmol/kg, a possible cumulative effect with repeated administration, the effect of morning administration, and the absence of similar benefits with twice-daily dosing [3]. However, the publication summarized several related experiments and included a single case of a higher dose being used, without sufficient data to establish a reproducible protocol. Therefore, it should not be considered a formal dose-range study.
In 1986, 18 individuals with chronic psychophysiological insomnia received six intravenous doses of 30 nmol/kg over the course of one week, after which the participants were monitored for another week [4]. The researchers described a gradual normalization of certain sleep parameters; however, the study was small and did not provide the comparative data needed to establish a clinical dosing standard.
In the 1987 polysomnographic study, 25 nmol/kg was administered intravenously over four nights in a double-blind, crossover trial. Although some sleep parameters changed in a favorable direction, most did not differ significantly from baseline or placebo. The researchers considered the overall improvement to be of little clinical significance [5].
In 1992, 16 individuals with chronic insomnia received intravenous infusions of 25 nmol/kg in the afternoon before the third, fourth, and fifth laboratory nights. Objective improvement was slight, subjective sleep quality did not improve, and the authors considered a significant therapeutic benefit unlikely [6].
DSIP has also been studied in areas other than insomnia. In an uncontrolled study of withdrawal symptoms, 67 participants with alcohol- or opioid-related symptoms received 25 nmol/kg intravenously as the sole experimental intervention. Approximately 27% participants were lost to follow-up or deemed ineligible for evaluation [8]. This study did not establish a dosing regimen for either withdrawal symptoms or sleep disorders, and its design does not allow for a reliable determination of efficacy.
In a later anesthetic experiment, 12 women received intravenous bolus doses of 25, 50, or 100 nmol/kg. DSIP was administered once while awake and again during isoflurane anesthesia. DSIP unexpectedly decreased delta rhythm and, at the lowest dose, appeared to lighten rather than deepen anesthesia [9]. This result shows why the sleep-related name or greater exposure should not be automatically equated with predictable sleep-promoting effects.
DSIP dosage table by study type
The table below presents the methods used in the studies to allow for an accurate comparison. The values in micrograms per kilogram are solely chemical conversions for native DSIP with a molecular weight of approximately 848.8 g/mol [10]. These are not recommended doses. Salts, excipients, glycine-containing preparations, analogs, and modified peptides may have different molecular weights and biological properties.
| Study and Level of Evidence | Model or population | Amount of DSIP | Route and time of administration | Frequency or duration | Main limitation |
|---|---|---|---|---|---|
| Schneider-Helmert et al., 1981 [1] | 6 healthy adults; controlled crossover study | 25 nmol/kg, chemically approx. 21.2 µg/kg of native DSIP | Slow intravenous infusion in the morning | A single application per condition | Very small sample size; this was not a study of insomnia treatment |
| Schneider-Helmert and Schoenenberger, 1981 [2] | 6 middle-aged people with chronic insomnia | 25 nmol/kg, ok. 21.2 µg/kg | Rapid intravenous administration before the observed sleep period | Single application | The effect was delayed; mild agitation was observed during the first hour |
| Schneider-Helmert, 1986 [4] | 18 people with chronic psychophysiological insomnia | 30 nmol/kg, approx. 25.5 µg/kg | Intravenously under the supervision of a sleep laboratory | 6 applications in a week; a week of observation | Small study; no recent studies on dose selection or long-term safety |
| Monti et al., 1987 [5] | Adults with chronic insomnia; a double-blind crossover study | 25 nmol/kg, ok. 21.2 µg/kg | Intravenously during research nights | 4 nights | Small clinical improvement compared to placebo/baseline |
| Bes et al., 1992 [6] | 16 people with chronic insomnia; double-blind parallel groups | 25 nmol/kg, ok. 21.2 µg/kg | Intravenously in the afternoon before laboratory nights 3–5 | 3 passes in a row | Poor objective results and no improvement in subjective sleep quality |
| Dick, Grandjean and Tissot, 1983 [8] | 67 individuals with alcohol or opioid withdrawal symptoms; uncontrolled study | 25 nmol/kg, ok. 21.2 µg/kg | Intravenously as an experimental sole intervention | The diagram is insufficiently described to establish a standard protocol. | High participant dropout rate and no placebo; this was not a dose-ranging study for sleep |
| Pomfrett et al., 2009 [9] | 24 women in an anesthetic study; 12 received DSIP | 25, 50, or 100 nmol/kg, approximately 21.2, 42.4, or 84.9 µg/kg | Intravenous bolus while the patient is awake and again during anesthesia | 2 applications under experimental conditions | A Study of Interactions with Anesthesia; Paradoxical EEG and Autonomic Findings |
| Susić and Masirević, 1985 [11] | Cats after 72 hours of REM sleep deprivation | 7 nmol/kg | homebound immediately after deprivation | Single dose; 8 hours of monitoring | Animal study with direct administration into the brain |
| Susić, Masirević, and Totić, 1987 [12] | 10 cats | 7 nmol/kg | Intra-chamber | Sharp sleep tracking | The route of administration in animals cannot be extrapolated to peripheral administration in humans |
| Susic, 1987 [13] | 8 cats | 120 nmol/kg | Subcutaneously | Acute examination | Animal data; changes in total sleep duration and sleep onset latency were inconsistent |
| Popovich et al., 2003 [14] | Female SHR mice; lifespan study | 2.5 µg per mouse, approx. 100 µg/kg, in Deltaran | Subcutaneously | 5 consecutive days of every month from the 3rd month of life until natural death | A preparation containing DSIP; a longevity study in animals, not a human sleep protocol |
The table shows why combining all the studied quantities of DSIP into a single „typical range” would be scientifically misleading. The doses varied more than tenfold, the routes of administration included slow intravenous infusion, direct brain administration, and subcutaneous administration in animals, and researchers analyzed very different outcomes—ranging from sleep phases to withdrawal symptoms, anesthesia, oxidative stress, and lifespan.
The species, route of administration, formulation, and purpose of the study are essential elements of every protocol. They must not be overlooked when interpreting the dose.
DSIP Dosage in Sleep Studies
The most frequently studied amount of DSIP in human sleep studies was 25 nmol/kg administered intravenously. However, repeating this value in several experiments does not mean it is a validated clinical dose.
With a molecular weight of native DSIP of approximately 848.8 g/mol, one nanomole of DSIP weighs about 0.8488 micrograms. This means that 25 nmol/kg is chemically equivalent to approximately 21.2 µg/kg, while 30 nmol/kg corresponds to approximately 25.5 µg/kg [10].
These calculations are intended solely to convert the units used in historical studies. They do not take into account the form of the peptide salt, purity, degradation, differences in bioavailability among routes of administration, distribution in the body, or individual health risks.
The clinical significance of these amounts also remains uncertain. At 25 nmol/kg, one study involving six people showed longer and less fragmented sleep [2], while another controlled crossover study showed changes of little clinical significance [5]. A double-blind study involving 16 people also showed no significant improvement in subjective sleep quality [6].
Simply administering a specific amount to study participants does not mean it is an effective dose. It is merely an experimental exposure applied under the specific conditions of a given study.
There are no recent published sleep studies establishing a fixed dose in micrograms for adults, a body-weight-based subcutaneous regimen, or an intranasal dose. Nor has it been demonstrated that changing the route of administration while maintaining the same body weight leads to similar concentrations of DSIP in the blood or brain.
For this reason, the fixed quantities popular on the internet cannot be described as scientifically validated doses of DSIP for sleep.
When to take DSIP and how long before sleep?
Published studies do not specify a reliable time for administering DSIP before sleep.
The timing of administration varied significantly between the studies. In the first controlled experiment, a slow intravenous infusion was administered in the morning, followed by an evaluation of both daytime sleep ability and the subsequent night's sleep [1].
In a study involving six individuals with insomnia, DSIP was administered intravenously in relation to the observed sleep period. A slight stimulation was observed in the first hour, whereas the sleep-promoting effect appeared mainly in the second hour [2].
In a 1992 study, DSIP was administered intravenously in the afternoon before the third, fourth, and fifth laboratory nights [6]. Such diverse methods do not allow for establishing a universal recommendation according to which DSIP should be used a specific number of minutes before sleep.
Additional uncertainty is introduced by a 1984 review of studies. According to the authors, morning administration increased daytime activity while simultaneously affecting nocturnal sleep, whereas twice-daily administration failed to reproduce the desired pattern [3].
This observation does not fit the simple model of DSIP as a short-acting sedative whose effect depends primarily on how close to bedtime it was administered. However, the result comes from small, early studies and has not been confirmed in modern circadian rhythm or pharmacokinetic studies.
No sufficiently large randomized human study has been conducted to directly compare administration in the morning, in the afternoon, and at bedtime. There is also no accepted clinical onset time for DSIP administered subcutaneously, intranasally, or orally. Online recommendations regarding the timing of administration should therefore be treated as extrapolations rather than established research standards.
How often was DSIP administered in the studies?
The frequency of DSIP administration in studies ranged from a single administration to multiple administrations over consecutive days. None of these regimens has been confirmed as optimal.
Single-dose studies were used to evaluate immediate sleep-related effects in healthy volunteers and individuals with insomnia [1,2].
In studies involving repeated administration, the regimens included, among others, four nights at a dose of 25 nmol/kg [5], three afternoon administrations of 25 nmol/kg prior to consecutive nights in the laboratory [6], and six administrations of 30 nmol/kg over the course of one week [4].
A 1984 review suggested that changes in sleep structure might accumulate after about four administrations, but simultaneously indicated that using DSIP twice daily provided no additional benefit [3]. These data are insufficient to establish once-daily, every-other-night, or maintenance administration schedules.
In animal experiments, completely different frequencies were used. Acute sleep studies often involved a single administration prior to EEG monitoring [11–13]. In contrast, in the lifespan study, Deltaran was administered subcutaneously for five consecutive days each month for a significant portion of the animals’ lives [14].
This long-term, intermittent regimen was intended to study aging and the incidence of cancer in mice, not to treat sleep disorders in humans. It therefore does not constitute evidence justifying the use of DSIP cycles in humans.
The frequency of administration also cannot be considered independently of the route of administration. A slow intravenous infusion results in a different concentration-over-time profile than subcutaneous, intranasal, or direct administration into the brain. Without pharmacokinetic data for specific routes of administration, simply copying the number of weekly doses does not replicate the original study protocol.
Can DSIP be used every night?
Published studies do not confirm that DSIP can be used safely and effectively every night.
In some studies of insomnia, DSIP was administered over several consecutive study nights [4–6], but these studies were short and involved a very small number of participants.
They were not designed to detect rare adverse effects, tolerance, changes in hormonal signaling, drug interactions, immune reactions, problems related to product contamination, or the effects of exposure lasting weeks or months. There is no reliable long-term database on the safety of daily DSIP use.
An early suggestion that repeated administration might produce a cumulative effect does not prove that long-term use every night is beneficial [3]. The apparent cumulative effect may result from delayed biological signaling, changes in sleep schedules, participants’ expectations, regression to the mean, or other factors.
The same publication also indicated that twice-daily administration did not increase the benefits related to sleep. Therefore, increasing the frequency did not simply lead to a greater effect.
Claims that DSIP should be discontinued after a certain number of days, that the development of tolerance requires scheduled breaks, or that intermittent use prevents receptor desensitization are not supported by controlled human studies. Not even a specific receptor for DSIP has been confirmed. Such regimens should therefore be treated as anecdotal suggestions for protocols rather than established pharmacological facts.
DSIP cycle length and study duration
Sleep studies in humans typically lasted from a single administration to about one week. However, this does not mean that a therapeutic „DSIP cycle” has been established.
The term „cycle” is commonly used in fitness and research peptide communities, but it does not mean the same thing as a scientifically validated treatment regimen.
A small study involving six people analyzed single administrations [1,2]. Monti and coworkers used four study nights [5]. Bes and coworkers administered DSIP before three consecutive laboratory nights during a five-night experiment [6]. The 1986 Schneider-Helmert study used six administrations over one week, followed by observation of the participants for another week [4].
The duration of these protocols was an element of the experimental design. It does not prove that three, four, six, or seven days represents the optimal duration of use.
Longer regimens used in animal experiments concerned completely different issues. Deltaran was administered to mice for five consecutive days each month, starting from the third month of life until natural death [14]. Other experiments involved short series during exposure to continuous light, cold, ischemia, or in aging studies.
None of these studies confirms a multi-week DSIP sleep cycle in humans, nor do they specify how long the interval between cycles should be.
A reliable study of treatment duration would require predefined endpoints for insomnia, an adequate number of participants, an appropriate comparator, monitoring during and after treatment, and an assessment of insomnia, rebound, tolerance, daytime functioning, and adverse effects. Such data for DSIP are currently lacking.
DSIP 2 mg, 5 mg, 10 mg, and 15 mg: vial size and dose
The designations DSIP 2 mg, 5 mg, 10 mg, or 15 mg typically refer to the declared total amount of material contained in the vial. They do not specify an amount whose safety or efficacy for single administration has been clinically confirmed.
Several different terms are often confused. The size or content of a vial refers to the declared total mass of the material in the package. Concentration refers to the amount of material per unit volume after preparation and depends on the final volume and the actual content of the product. A dose refers to the amount administered at one time. Cumulative exposure is the total amount administered over a specified period of time. Bioavailable exposure, on the other hand, refers to the portion of the substance that reaches the circulation or the relevant tissue and depends, among other factors, on the route of administration, formulation, stability, absorption, and metabolism.
A 5-mg vial is therefore not automatically a „5-mg dose.” The label does not specify how many administrations should be made from a single vial, nor does it confirm the identity, purity, sterility, potency, stability, or absence of endotoxin contamination. A larger vial also does not imply stronger scientific evidence or a longer validated cycle.
The quantity listed on a commercial vial should not automatically be equated with the research material used in historical experiments. In human studies, specific synthetic peptide preparations were used under controlled conditions, and doses were typically expressed in nmol/kg.
Native DSIP has a molecular weight of approximately 848.8 g/mol, while the molecular weight of DSIP acetate is reported to be approximately 908.9 g/mol [10,15]. The salt form, counterions, water content, purity, and method of reporting the peptide content can all affect mass calculations. Without proper analytical verification, calculations based solely on the product label may appear precise, even though the actual amount remains uncertain.
For these reasons, this article does not provide information on reconstitution ratios, conversions to syringe units, instructions for administering injections, or recommendations for dividing the contents of a vial into individual doses. Published DSIP studies do not support such self-administration procedures.
DSIP Internet Protocols and Published Research
Most of the DSIP protocols described online differ from the methods used in peer-reviewed studies involving human participants.
Vendor websites, forums, social media, and peptide-related communities often describe fixed subcutaneous amounts expressed in micrograms, administration near bedtime, daily use for several weeks, or alternating periods of use and breaks.
These protocols are often repeated without supporting pharmacokinetic studies in humans, randomized trials using the same route of administration, or independent verification of the product itself. Repeating the same protocol on multiple websites does not transform an anecdotal regimen into clinical evidence, especially when websites may copy information from one another.
Published studies on sleep in humans were quite different. In most cases, approximately 25–30 nmol/kg was administered intravenously under the supervision of researchers [1–6]. Sleep was monitored using polysomnography, and participants were observed according to specific protocols under controlled conditions.
Even under these conditions, the results regarding efficacy were inconsistent. There is no established scientific evidence showing that the fixed subcutaneous dose promoted online provides exposure equivalent to the body-weight-dependent intravenous infusion used in historical studies.
Similar caution is needed when using intranasal administration. Nasal delivery can vary depending on the formulation, delivery device, droplet size, nasal anatomy, obstruction, application technique, and enzymatic degradation. The discussed peer-reviewed studies on human insomnia do not specify an intranasal dose of DSIP or a validated nasal spray concentration.
Intranasal experiments on animals or studies of modified fusion peptides designed to cross the blood-brain barrier cannot be directly translated into an intranasal DSIP protocol for humans.
The hierarchy of evidence should therefore remain clear. A controlled human study using the same molecule and route of administration provides stronger evidence than an uncontrolled report involving humans. Animal experiments constitute preclinical evidence, receptor and cellular studies provide mechanistic data, and online user reports are anecdotal in nature. Current social media-based dosing regimens remain at the lowest level of this hierarchy.
Why can't the DSIP dosing calculator determine a safe dose?
A dosing calculator can perform mathematical calculations or take body weight into account, but it cannot replace the missing clinical data needed to determine a safe dose.
Converting nmol/kg to µg/kg requires knowing the molecular weight of the peptide. For native DSIP, the mathematical relationship is:
µg/kg = nmol/kg × 0.8488
Therefore, 25 nmol/kg corresponds to approximately 21.2 µg/kg, and 30 nmol/kg to approximately 25.5 µg/kg [10].
This is purely a unit conversion. It does not determine whether a given exposure is effective, what route of administration should be used, how much peptide reaches the brain, or whether a specific preparation actually contains native DSIP of the assumed molecular weight.
The calculator also does not account for differences in bioavailability. Intravenous administration introduces the material directly into the circulation, whereas subcutaneous, intranasal, and oral administration involve different absorption and degradation processes.
Mathematical calculations will not correct an erroneous label, peptide aggregation, the presence of impurities, differences between salt forms, degradation during storage, or microbial contamination. Nor will they account for the type of sleep disorder, cardiovascular status, risk of respiratory depression, use of sedatives, exposure to alcohol or opioids, pregnancy, or other clinical factors unless a validated DSIP dosage model exists.
Additional uncertainty is created by converting doses from animals to humans. A dose given in µg/kg in mice cannot be safely converted by simply multiplying it by the human body weight. Allometric scaling can be useful in the early stages of formal drug development, but it provides only a preliminary toxicological estimate and requires subsequent pharmacokinetic studies, safety assessments, and controlled dose-escalation trials.
Therefore, it is not possible to translate cat studies with 7 nmol/kg administered intracerebroventricularly, a subcutaneous experiment with 120 nmol/kg in cats, or the Deltaran protocol of approximately 100 µg/kg in mice into instructions for human use [11–14].
FAQ: DSIP dosage
What is the standard dose of the DSIP peptide?
There is no standard or approved dose of the DSIP peptide. In historical human sleep studies, 25 nmol/kg intravenously was most commonly used, while one repeated-administration study used 30 nmol/kg intravenously [1–6]. These values describe researcher-supervised experiments and are not recommended doses.
What dosage of DSIP has been studied in relation to sleep?
The best-documented studies of sleep in humans used 25 nmol/kg administered via slow infusion or another controlled intravenous method. The results were inconsistent. Some very small early studies reported beneficial changes in sleep, while later controlled studies showed limited clinical significance or no significant improvement in subjective sleep quality [1,2,5,6].
When should DSIP be taken before bed?
No validated time interval before bedtime has been established. In human studies, DSIP was administered intravenously in the morning, in the afternoon, or around the time of the observed sleep period. In one small study, mild stimulation was observed during the first hour, and a sleep-inducing effect was observed primarily during the second hour [2]. However, this finding cannot be generalized to provide a recommendation regarding the timing of administration via other routes.
How often was DSIP administered in insomnia studies?
Protocols involved a single administration, three or four consecutive test nights, and six administrations within a single week [1–6]. No study has established the optimal frequency, and reliable data do not support long-term use every night.
Can DSIP be used every night for a month?
There are no adequate data from human studies confirming the safety or efficacy of daily DSIP use for one month. Published studies on insomnia were short-term, involved a small number of participants, and typically used supervised intravenous administration. The monthly regimens described online have not been validated in controlled clinical trials.
Is 5 mg the dose of DSIP?
Not necessarily. „5 mg” usually refers to the declared total amount of material in the vial, not a validated single-dose amount. The label does not specify the protocol, route, or frequency of administration; it does not confirm purity; and it does not prove that the material is equivalent to the native DSIP used in the studies.
Are the 2 mg, 5 mg, 10 mg, and 15 mg DSIP vials clinically different?
They differ in their stated total weight of the material, but none of these vial sizes specifies a clinical dose. A larger vial does not imply greater efficacy, higher potency, or a longer safe cycle. The actual content and quality of the product also cannot be determined solely based on the size of the vial.
Can the test dose of 25 nmol/kg be converted to milligrams?
It can be calculated mathematically using the molecular weight of native DSIP; however, the resulting value still describes historical exposure in an intravenous study, not the recommended dose. Such a conversion does not allow the protocol to be adapted for subcutaneous, intranasal, or oral administration, nor does it determine safety for a specific individual.
Is there a published subcutaneous dose of DSIP for insomnia in humans?
The main peer-reviewed studies on insomnia in humans discussed in the literature used intravenous administration. Subcutaneous studies on sleep have been conducted in animals, including cats, but they do not specify a subcutaneous dose for humans [13]. The subcutaneous regimens frequently cited online are therefore anecdotal or commercial protocols, rather than validated clinical standards.
Is there a published intranasal dose of DSIP for sleep in humans?
The peer-reviewed literature on insomnia in humans discussed here does not specify a validated intranasal dose of DSIP. The results of animal studies, studies on other DSIP analogs, or modified fusion peptides cannot be used as the basis for a human intranasal aerosol protocol.
Does taking body weight into account make the online DSIP calculator reliable?
No. Calculations based on body weight take into account only one factor. They do not determine bioavailability, product identity, equivalence of different routes of administration, dose-response relationships, maximum tolerated exposure, drug interactions, or whether the DSIP is appropriate for a specific individual or research question.
What is the safest DSIP dosing protocol?
No DSIP dosing protocol has been established that could be considered safe enough to recommend for use on its own. DSIP remains unapproved for the uses discussed, and its efficacy, long-term safety, product quality, and route-of-administration-dependent dosing remain uncertain. Persistent sleep problems or withdrawal symptoms should be evaluated by a qualified healthcare professional in accordance with recognized diagnostic and therapeutic standards.
Limitations of the Available Data
The available literature on dosing does not allow for the establishment of a standard DSIP protocol, as human data come primarily from small studies conducted several decades ago and have limited independent replication.
Several positive reports regarding sleep came from the same research network, while subsequent controlled studies showed weak or clinically insignificant effects. The number of participants was too small to adequately assess rare adverse effects or differences between patient subgroups. Long-term exposure was also not adequately studied.
Routes of administration and formulations represent another significant limitation. Major studies of sleep in humans have used intravenous DSIP, while current online discussions focus primarily on other routes of administration.
Native DSIP, DSIP acetate, phosphorylated analogs, Deltaran, and modified peptide constructs should not be considered interchangeable. In animal studies, direct administration into the brain, subcutaneous injections, and other routes of administration were also used in species with different physiologies. Direct extrapolation of such doses to humans is therefore inappropriate.
Finally, the dose described in a scientific publication is not the same as the approved or recommended dose. The research methods describe what the scientists tested. This does not automatically imply confirmed clinical efficacy, regulatory approval, pharmaceutical quality, or a safe protocol for home use.
If older abstracts do not contain precise information about the duration of the infusion, the formulation, or the administration regimen, this information should be marked as unavailable, rather than reconstructed based on commercial sources or online communities.
Disclaimer
This article summarizes published research methods solely for educational and scientific-informational purposes. It does not constitute medical advice, a prescription, reconstitution instructions, or an injection protocol.
Delta sleep-inducing peptide (DSIP/emideltide) is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of insomnia, improving sleep, withdrawal symptoms, pain, promoting longevity, or any other uses discussed in this article.
The available evidence is limited; most of it comes from older studies and is based in part on preclinical data. No standard dose for humans, administration schedule, route of administration, frequency, or duration of treatment has been established.
Tables presenting research findings and mathematical calculations should not be used to plan the independent use of an unapproved peptide.
References
- Schneider-Helmert, D., Gnirss, F., Monnier, M., Schenker, J., & Schoenenberger, G. A. (1981). Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. International Journal of Clinical Pharmacology, Therapy, and Toxicology, 19(8), 341–345. https://pubmed.ncbi.nlm.nih.gov/6895513/
- Schneider-Helmert, D., & Schoenenberger, G. A. (1981). The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia, 37(9), 913–917. https://doi.org/10.1007/BF01971753
- Schneider-Helmert, D. (1984). DSIP in insomnia. European Neurology, 23(5), 358–363. https://doi.org/10.1159/000115714
- Schneider-Helmert, D. (1986). Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs. European Neurology, 25(6), 448–453. https://doi.org/10.1159/000116050
- Monti, J. M., Debellis, J., Alterwain, P., Pellejero, T., & Monti, D. (1987). Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. International Journal of Clinical Pharmacology Research, 7(2), 105–110. https://pubmed.ncbi.nlm.nih.gov/3583493/
- Bes, F., Hofman, W., Schuur, J., & Van Boxtel, C. (1992). Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: A double-blind study. Neuropsychobiology, 26(4), 193–197. https://doi.org/10.1159/000118919
- U.S. Food and Drug Administration. (n.d.). Emideltide: UNII YN28Z5YZ73. Global Substance Registration System. https://precision.fda.gov/uniisearch/srs/unii/yn28z5yz73
- Dick, P., Grandjean, M. E., & Tissot, R. (1983). Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors. Neuropsychobiology, 10(4), 205–208. https://doi.org/10.1159/000118012
- Pomfrett, C. J. D., Dolling, S., Anders, N. R. K., Glover, D. G., Bryan, A., & Pollard, B. J. (2009). Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia. European Journal of Anaesthesiology, 26(2), 128–134. https://doi.org/10.1097/EJA.0b013e32831c8644
- National Center for Biotechnology Information. (2026). PubChem compound summary for CID 68816, delta sleep-inducing peptide. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/68816
- Susić, V., & Masirević, G. (1985). Effects of delta sleep-inducing peptide on sleep cycle of cats deprived of paradoxical sleep. Archives Internationales de Physiologie et de Biochimie, 93(4), 271–277. https://doi.org/10.3109/13813458509079606
- Susić, V., Masirević, G., & Totić, S. (1987). Effects of delta sleep-inducing peptide on wakefulness and sleep patterns in the cat. Brain Research, 414(2), 262–270. https://doi.org/10.1016/0006-8993(87)90006-0
- Susić, V. (1987). Effects of subcutaneous administration of delta sleep-inducing peptide on the sleep-waking cycle in the cat. Physiology & Behavior, 40(5), 569–572. https://doi.org/10.1016/0031-9384(87)90098-9
- Popovich, I. G., Voitenkov, B. O., Anisimov, V. N., Ivanov, V. T., Mikhaleva, I. I., Zabezhinski, M. A., Alimova, I. N., Baturin, D. A., Zavarzina, N. Y., Rosenfeld, S. V., Semenchenko, A. V., & Yashin, A. I. (2003). Effect of Deltaran, a preparation containing delta-sleep-inducing peptide, on biomarkers of aging, lifespan, and spontaneous tumor incidence in female SHR mice. Mechanisms of Ageing and Development, 124(6), 721–731. https://doi.org/10.1016/S0047-6374(03)00082-4
- National Center for Biotechnology Information. (2026). PubChem compound summary for CID 163337005, DSIP acetate. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/163337005